FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average I	hurden									

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol Aptevo Therapeutics Inc. [APVO]										5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
White Marvin L					<u></u>	increase inc. [Ar vo]									X Director				10% C	wner	
(Last)	(Fi	rst) (Middle)		3. Da	ate o	f Earlies	t Trans	action (M	lonth/	Day/Year)				X Officer (give tit below)			Other (specify below)			
2401 4TH AVENUE, SUITE 1050				12/04/2018										President and CEO							
(Street)					4. If	Ame	ndment,	Date o	f Original	Filed	(Month/Da	ay/Ye	ar)		Indiv ne)	idual o	r Joint/Group	Filing (C	heck A	pplicable	
SEATTL	E WA 9		98121												X	Forn	m filed by One Reporting Person				
(City)	(St	ate) (Zip)													Form filed by More than One Reporting Person					
		Tabl	e I - No	n-Deriva	ative	Sec	curitie	s Acc	quired,	Dis	posed o	f, o	r Ben	eficia	lly	Owne	ed				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				ay/Year) if a		A. Deemed Execution Date, f any Month/Day/Year)		Transaction Dispose Code (Instr. 5)		Disposed	ities Acquired (A) d Of (D) (Instr. 3, 4			4 and S B		Securities Beneficially		ship rect direct 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D) Pr		Price		Transaction(s) (Instr. 3 and 4)				(111501.4)	
Common Stock 12/04				2018			P		10,000	0 A \$		\$2.3	8(1)	203,603		D					
		Та									sed of, onvertib				/ Ov	vned					
Derivative Conversion Da		3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	n Date,	4. Transac Code (I 8)		5. Nu of Deriv Secul Acqui (A) on Dispo of (D) (Instrand 5	ative rities ired osed	6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Exercisable Date			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amoun or Numbe of Title Shares		ount nber				Own Form Direc or In (I) (Ir		11. Nature of Indirect Beneficial Ownership (Instr. 4)	

Explanation of Responses:

1. The purchase price of \$2.38 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from \$2.38 to \$2.39. Mr. White undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

/s/ Carl A. Valenstein, attorneyin-fact 12/06/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.